Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.52 |
| ▸ | HRH1 | P35367 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | TACR1 | P25103 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | DUT | P33316 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9501904 | 0.81 | HPGD (0.61) | TDP1TACR1LMNAALDH1A1HPGD | |
| Acetic Acid SCHEMBL9501909 | 0.78 | HPGD (0.58) | TDP1TACR1LMNAALDH1A1HPGD | |
| SCHEMBL1174449 | 0.74 | SMN1; SMN2 (0.58) | LMNAMAPK1KDM4EALDH1A1HPGD | |
| SCHEMBL1174179 | 0.74 | SMN1; SMN2 (0.58) | LMNAMAPK1KDM4EALDH1A1HPGD | |
| SCHEMBL1206380 | 0.74 | LMNA (0.52) | LMNAMAPK1KDM4EALDH1A1HPGD | |
| SCHEMBL1206385 | 0.74 | LMNA (0.52) | LMNAMAPK1KDM4EALDH1A1HPGD | |
| SCHEMBL29103977 | 0.74 | SMN1; SMN2 (0.58) | LMNAMAPK1KDM4EALDH1A1HPGD | |
| SCHEMBL14368105 | 0.74 | AOC3 (0.56) | HTR2AHRH1LMNAKDM4EALDH1A1 | |
| SCHEMBL14338231 | 0.74 | AOC3 (0.56) | HTR2AHRH1LMNAKDM4EALDH1A1 | |
| SCHEMBL29988941 | 0.73 | LMNA (0.50) | LMNAMAPK1KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9579325-B2 | Modulators of TNF-α signaling | GENZYME CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| EP-1294699-B1 | MODULATORS OF TNF- ALPHA SIGNALLING | GENZYME CORP (US) | 2016-04-13 | — | — | EP | disclosed |
| US-20150126512-A1 | Modulators Of TNF-Alpha Signaling | GENZYME CORPORATION (US) | 2015-05-07 | — | — | US | disclosed |
| US-8921547-B2 | Modulators of TNF-α signaling | GENZYME CORPORATION (US) | 2014-12-30 | — | — | US | disclosed |
| US-20130310388-A1 | Modulators of TNF-Alpha Signaling | GENZYME CORPORATION (US) | 2013-11-21 | — | — | US | disclosed |
| US-8518999-B2 | Modulators of TNF-αsignaling | GENZYME CORPORATION (US) | 2013-08-27 | — | — | US | disclosed |
| US-20060173010-A1 | Modulators of TNF-alpha signaling | GENZYME | 2006-08-03 | — | — | US | disclosed |
| US-7034031-B2 | Modulators of TNF-α signaling | GENZYME CORPORATION (US) | 2006-04-25 | — | — | US | disclosed |
| US-6969728-B2 | Antiinflammatory agents | GENZYME CORPORATION (US) | 2005-11-29 | — | — | US | disclosed |
| US-20040171617-A1 | treatment for disorders and diseases, such as chronic inflammation, tissue breakdown and cancer | GENZYME CORPORATION | 2004-09-02 | — | — | US | disclosed |
| EP-1294699-A2 | MODULATORS OF TNF- ALPHA SIGNALLING | GENZYME CORPORATION (US) | 2003-03-26 | — | — | EP | disclosed |
| US-20020119988-A1 | Antiinflammatory agents | GENZYME CORPORATION | 2002-08-29 | — | — | US | disclosed |
| WO-2001087849-A2 | MODULATORS OF TNF- ALPHA SIGNALING | GENZYME CORPORATION (US) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119988-A1 | Antiinflammatory agents | TNF, TNFRSF1A, CD40 | HTR2A 1056/4885HRH1 219/4885TDP1 3193/4885 |
| US-20040171617-A1 | treatment for disorders and diseases, such as chronic inflammation, tissue breakdown and cancer | TNF, TNFRSF1A, CD40 | HTR2A 2433/4885HRH1 1087/4885TDP1 2531/4885 |
| US-20150126512-A1 | Modulators Of TNF-Alpha Signaling | TNF, TNFRSF1A, TNFRSF9 | HTR2A 1440/4885HRH1 950/4885TDP1 3459/4885 |
| US-20060173010-A1 | Modulators of TNF-alpha signaling | TNF, TNFRSF1A, TNFRSF9 | HTR2A 1440/4885HRH1 950/4885TDP1 3459/4885 |
| US-20130310388-A1 | Modulators of TNF-Alpha Signaling | TNF, TNFRSF1A, TNFRSF9 | HTR2A 1440/4885HRH1 950/4885TDP1 3459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.